Figure 3. SMIP-016^GV can mediate cytotoxicity through effector cells. (A) Intact antibodies, F(ab)’2 or SMIP bound to plates induced TNF from peripheral blood monocytes (n = 4). (B) SMIP-016^GV mediates enhanced antibody-dependent cellular phagocytosis (ADCP) by monocyte-derived macrophages (MDM) of primary CLL cells compared with SMIP-016, as measured by flow cytometry (n = 3) (p < 0.05). (C) Induction of CD107a on the surface of CD56⁺ NK cells by SMIP-016^GV, as measured by flow cytometry (n = 6). (D) Enhanced induction of interferon gamma from NK cells by SMIP-016^GV compared with SMIP-016 (p = 0.009) (n = 4). (E, F) ADCC with normal donor NK cell effectors and Raji (E) or 697 (F) targets. SMIP-016^GV shows enhanced ADCC function in the CD37 expressing Raji cells compared with SMIP-016 (p = 0.0013 of average of all E:T ratio > 0), but no activity in the 697 cells (n = 3).